# Thymosin Alpha-1 FAQ: Mechanism, Benefits, Safety & Approval Status

> Thymosin Alpha-1 answered: what it is and does, how it differs from TB-500, whether it boosts immunity, its benefits and safety, and its FDA-approval status — cited where quantitative.

Direct, cited answers to what people ask most about the thymic immunomodulator.

## What is thymosin alpha 1?

Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus as part of thymosin fraction 5; Goldstein and colleagues purified it and determined its complete sequence in 1977 [1]. It is an immune-modulating peptide cleaved in the body from the larger precursor prothymosin alpha.

## What does thymosin alpha 1 do?

It tunes the immune system. Signaling through Toll-like receptors (TLR2/TLR9) on dendritic cells, it promotes their maturation and antigen presentation, drives T-cell maturation and a Th1 response, and in parallel activates an IDO-dependent regulatory arm that generates regulatory T cells [5]. The effect is dual: restore effector immunity where it is weak, restrain it where it is excessive.

## What is TA1 peptide?

TA1 (also written Tα1) is shorthand for thymosin alpha-1, the 28-amino-acid thymic immunomodulatory peptide [1]. Its synthetic, sequence-identical drug form is named thymalfasin. The label refers to the same molecule whether written as TA1, Tα1, thymalfasin, or thymosin alpha-1.

## Is TB-500 the same as thymosin alpha 1?

No. TB-500 is a fragment of thymosin beta-4, a separate 43-amino-acid actin-binding peptide involved in cell migration and tissue repair. Thymosin alpha-1 is a different 28-amino-acid immune-signaling peptide [1]. Different sequence, different size, different mechanism, different use — and it is thymosin beta-4, not alpha-1, that is WADA-prohibited.

## Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?

They are distinct molecules. Thymosin alpha-1 (28 amino acids) is an immunomodulator that signals through dendritic-cell TLRs to retune immunity [5]. Thymosin beta-4 (43 amino acids), source of TB-500, is an actin-binding peptide acting on cell migration and tissue repair. On a gel they resolve as separate bands at separate weights; only thymosin beta-4 sits in the WADA-prohibited category.

## Where does thymosin alpha 1 come from in the body?

It is endogenous. Thymosin alpha-1 is cleaved in the body from a 113-amino-acid precursor protein called prothymosin alpha, and it is associated with the thymus gland [1]. It was first purified from calf thymus tissue. Circulating levels decline with age and are reduced in some chronic inflammatory and autoimmune conditions.

## Is thymosin alpha 1 a steroid?

No. Thymosin alpha-1 is a peptide — a 28-amino-acid chain of protein building blocks — not a steroid hormone [1]. It does not act through steroid receptors and has no anabolic or androgenic activity. Its action is immunomodulatory, working through immune-cell receptors rather than the pathways steroids use.

## Does thymosin alpha 1 boost the immune system?

It modulates rather than simply boosts. It promotes dendritic-cell maturation, Th1 polarization, and cytotoxic T-cell activity while also generating regulatory T cells through an IDO-dependent arm [5]. In severe COVID-19 it increased T-cell numbers and reversed T-cell exhaustion [6]. The honest framing is a two-way tuning effect, not a one-directional boost.

## What are the benefits of thymosin alpha 1?

In the literature the clearest benefits are in chronic hepatitis B, where combination therapy raised HBeAg seroconversion to 45.1% versus 15.2% [10], and as an immune-restorative adjunct. Community members anecdotally report fewer or shorter colds and faster recovery when run-down — impressions, not measured outcomes, covered on the [effects page](/effects).

## What is thymosin alpha 1 used for?

Abroad it is used chiefly for chronic hepatitis B and as an immune adjuvant, and it has been studied in sepsis, severe COVID-19, and as a cancer adjuvant. A reappraisal positions it as an immunostimulatory adjuvant alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, acting through dendritic cells and the adaptive immune response [14].

## Is thymosin alpha 1 FDA-approved?

No. Thymosin alpha-1 (thymalfasin) is not approved for marketing in the United States. It is approved as a drug in roughly 35 other countries, chiefly for hepatitis B and immune support [4]. In the US, availability is limited to investigational and compounding contexts; some historical orphan-drug designations existed but are not marketing approvals.

## Who should not take thymosin alpha 1?

The literature raises theoretical caution for people with established autoimmune disease (an immunostimulant broadly enhancing effector immunity) [16] and for solid-organ transplant recipients (it could work against intentional immunosuppression) [5]. Pregnancy and lactation data are absent [4]. These are reasons for caution, not clinical findings, and this site gives no medical advice.

## How long should you take thymosin alpha 1?

Trial durations varied by indication: twice-weekly courses over months in chronic hepatitis B, intensive 5-to-7-day regimens in sepsis, and daily dosing in COVID-19 cohorts [4][3]. These are study protocols in specific patient populations, not guidance. This site reports what was studied and does not recommend any duration of use.

## How long does it take for thymosin alpha 1 to work?

There is no defined consumer onset; effects in trials are measured as clinical endpoints over weeks, not as a felt sensation. Pharmacokinetically, a subcutaneous dose peaks in blood within about one to two hours with a roughly two-hour elimination half-life [4]. Any immunological change is biochemical and tracked by lab markers, not by how a person feels.

## What is the dosing protocol for thymosin alpha 1?

Across the literature, single subcutaneous doses ranged from 0.8 to 6.4 mg, with multiple-dose regimens of 1.6 to 16 mg over five to seven days; the standard hepatitis regimen was 1.6 mg subcutaneous twice weekly [4]. These are study parameters by population and route, reported here for accuracy — not a protocol for any individual to follow.

## How does thymosin alpha 1 make you feel?

Most people report feeling nothing in particular, which is expected for an immune modulator whose effects are biochemical rather than perceptible [4]. Anecdotally, some describe a vague sense of resilience or steadier energy during recovery; a minority note a transient flu-like day or injection-site irritation. These are reports, not measured effects — see the [effects page](/effects).

## How much thymosin alpha 1 should I take?

This site does not advise any amount. For context only, studies used single subcutaneous doses of 0.8 to 6.4 mg and a typical 1.6 mg twice-weekly regimen in specified patient populations [4]. Those are research parameters, not recommendations. Decisions about any unapproved peptide should involve a qualified clinician, not a website.

## When is the best time to take thymosin alpha 1?

The literature does not establish an optimal time of day; trial protocols specified frequency (for example, twice weekly or every 12 hours) rather than a particular hour [4][2]. Because this is an immunomodulator dosed by clinical schedule in studies, there is no evidence-based 'best time,' and this site offers no timing guidance.

## Is thymosin alpha 1 safe to take?

In studied clinical settings it is generally well tolerated; large post-marketing surveillance identifies mild injection-site reactions and occasional transient flu-like symptoms as the dominant adverse events, with no documented organ toxicity at studied doses [17]. Separately, unregulated research-grade material carries identity, purity, and sterility risks [4]. This is not a safety endorsement of unapproved personal use.

## Does thymosin alpha 1 help cancer?

It is studied as an adjuvant, not a cure. A reappraisal frames it as an immunostimulatory add-on to chemo- and immunotherapy that may help turn a cold tumour hot and reduce checkpoint-inhibitor toxicity [14]; mechanistically it blocked myeloid-derived suppressor cells in lung cancer by inhibiting VEGF [12]. Evidence is supportive but combination-context and not a standalone treatment claim.

## Is thymosin alpha 1 worth it?

That depends on setting and cannot be answered as personal advice. The strongest evidence is in chronic viral hepatitis; the largest, most rigorous sepsis trial was null (hazard ratio 0.99, P=0.93) [3]. Combined with its US non-approval and research-grade quality concerns, the honest summary is: real but qualified evidence, strongest in specific indications.

## Does thymosin affect aging?

Circulating thymosin alpha-1 levels decline with age, and immune decline (immunosenescence) is the rationale behind vaccine-adjuvant research with the peptide [1]. But no trial shows it slows aging itself; the studied benefits are immunological, in defined disease settings. Claims that it is an anti-aging therapy go beyond what the evidence supports.

---

A mechanism-first reading of the Thymosin Alpha-1 literature — each finding resolved to its own study like a band on a blot, the null sepsis trial kept in plain view; no clinic behind the bench, and nothing here dosed, prescribed, or sold.